norethindrone acetate and ethinyl estradiol

norethindrone acetate and ethinyl estradiol

a combination oral contraceptive containing a progestin (norethindrone) and an estrogen (ethinyl estradiol).
indications It is prescribed for contraception, the treatment of acne and moderate to severe vasomotor symptoms in menopause, and the prevention of osteoporosis in postmenopausal women at high risk. Unlabeled uses include hypermenorrhea, endometriosis, and female hypogonadism.
contraindications Thrombophlebitis, severe hypertension, coronary artery disease, diabetes with vascular complications, migraine headaches, breast or reproductive organ cancer, unusual vaginal bleeding, gallbladder disease, liver dysfunction or tumor, or known hypersensitivity to this drug prohibits its use. It is not given during lactation, pregnancy, or suspected pregnancy or to women over the age of 35 who smoke more than 15 cigarettes per day.
adverse effects Among the more serious adverse effects are thrombophlebitis, embolism, hypertension, myocardial infarction, cerebrovascular accident, depression, headache, premenstrual syndrome, cramps, breakthrough bleeding, porphyria, embolism, jaundice, and gallbladder disease.
References in periodicals archive ?
The company also says that it has received final approval from the FDA for norethindrone acetate and ethinyl estradiol tablets (0.
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.
The company added that Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.
According to the company, its US Food and Drug Administration (FDA) approved Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.